Table 1 Results according to the ECCO2R medical device
From: Proceedings of Réanimation 2018, the French Intensive Care Society International Congress
Medical device | Hemolung (n = 40) | iLA Activve (n = 7) |
|---|---|---|
Age (yrs): mean ± SD | 66.7 ± 11.9 | 68.2 ± 7.6 |
Sex (men): n (%) | 26 (65%) | 3 (42%) |
Indications | ||
COPD: n (%) | 19 (47.5%) | 3 (42%) |
FEV1%th.: mean ± SD | 43.8 ± 20.5 | missing data |
ARDS: n (%) | 14 (35%) | 4 (58%) |
PaO2/FiO2: mean ± SD | 157 ± 62 | 139 ± 45 |
Severe asthma: n (%) | 4 (10%) | 0 (0%) |
Other: n (%) | 4 (10%) | 0 (0%) |
Ending cause: n (%) | ||
Success | 22 (55%) | 3 (42%) |
Adverse events | 9 (22.5%) | 2 (29%) |
Death | 5 (12.5%) | 2 (29%) |
Futility | 4 (10%) | 0 (0%) |
Adverse events n (%) | 26 (65%) | 3 (42%) |
Hemolysis | 20 | 0 |
Clinical hemolysis | 10 | 0 |
Bleeding | 14 | 1 |
Thrombosis | 2 | 2 |
Infection | 0 | 1 |
Treatment of adverse events n (%) | ||
Surgery | 1 (2.5%) | 0 (0%) |
Interventional radiology | 2 (5%) | 0 (0%) |
Transfusion | 9 (22.5%) | 0 (0%) |
In-ICU mortality: n (%) | 18 (45%) | 3 (42%) |
In relation with ECCO2R | 3 (7.5%) | 0 (0%) |